Modification of amphetamine effects by intracerebrally administered anticholinergic agents.
D000818:Animals; D001285:Atropine / Q000008:administration & dosage / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D003342:Corpus Striatum; D003913:Dextroamphetamine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004357:Drug Synergism; D005021:Ethylamines / Q000494:pharmacology; D005917:Globus Pallidus; D006801:Humans; D007267:Injections; D007274:Injections, Intraperitoneal; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009966:Orphenadrine / Q000008:administration & dosage / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology*; D011728:Pyridones / Q000494:pharmacology; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D013997:Time Factors
D005021:Ethylamines; D010276:Parasympatholytics; D011728:Pyridones; D001285:Atropine; D009966:Orphenadrine; D003913:Dextroamphetamine